MedTrace Logo

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

NCT01055847 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2010-01-26

No results posted yet for this study

Summary

This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.

Conditions

Interventions

DRUG

Aztreonam for Inhalation (AI)

Aztreonam for Inhalation

DRUG

Placebo

Saline Placebo

Sponsors & Collaborators

Principal Investigators

  • Ronald L Gibson, Jr., MD · Children's Hospital and Regional Medica Center, Seattle, WA

  • George Retsch-Bogart, MD · University of North Carolina Hospitals, Chapel Hill, NC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2004-08-31
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01055847 on ClinicalTrials.gov